

# Accepted Manuscript

Synthesis of novel pyrazoles incorporating a phenothiazine moiety: Unambiguous structural characterization of the regioselectivity in the 1,3-dipolar cycloaddition reaction using 2D HMBC NMR spectroscopy

Ahmed E.M. Mekky, Tamer S. Saleh, Abdullah S. Al-Bogami



PII: S0040-4020(13)00958-7

DOI: [10.1016/j.tet.2013.06.028](https://doi.org/10.1016/j.tet.2013.06.028)

Reference: TET 24504

To appear in: *Tetrahedron*

Received Date: 18 April 2013

Revised Date: 29 May 2013

Accepted Date: 10 June 2013

Please cite this article as: Mekky AEM, Saleh TS, Al-Bogami AS, Synthesis of novel pyrazoles incorporating a phenothiazine moiety: Unambiguous structural characterization of the regioselectivity in the 1,3-dipolar cycloaddition reaction using 2D HMBC NMR spectroscopy, *Tetrahedron* (2013), doi: 10.1016/j.tet.2013.06.028.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


**Synthesis of novel pyrazoles incorporating a phenothiazine moiety: Unambiguous structural characterization of the regioselectivity in the 1,3-dipolar cycloaddition reaction using 2D HMBC NMR spectroscopy**

Ahmed E. M. Mekky<sup>1,2</sup>, Tamer S. Saleh<sup>1,3</sup>, Abdullah S. Al-Bogami<sup>1,\*</sup>

<sup>1</sup>Chemistry Department, Faculty of Science, King Abdulaziz University, North Jeddah, P.O. Box 80203, Jeddah 21589, Saudi Arabia

<sup>2</sup>Chemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt

<sup>3</sup>Green Chemistry Department, National Research Centre, Dokki, Cairo 12622, Egypt



\* Corresponding author. Fax: +966 26400376; Tel: +966 554433416; E-mail: chem\_org@hotmail.com

**Synthesis of novel pyrazoles incorporating a phenothiazine moiety:  
Unambiguous structural characterization of the regioselectivity in the 1,3-  
dipolar cycloaddition reaction using 2D HMBC NMR spectroscopy**

Ahmed E. M. Mekky<sup>1,2</sup>, Tamer S. Saleh<sup>1,3</sup>, Abdullah S. Al-Bogami<sup>1,\*</sup>

<sup>1</sup>*Chemistry Department, Faculty of Science, King Abdulaziz University, North Jeddah, P.O. Box 80203, Jeddah 21589, Saudi Arabia*

<sup>2</sup>*Chemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt*

<sup>3</sup>*Green Chemistry Department, National Research Centre, Dokki, Cairo 12622, Egypt*

**ABSTRACT**

An efficient and attractive regioselective synthesis of a series of novel pyrazoles containing a phenothiazine moiety was achieved utilizing microwave irradiation. Unambiguous structural assignment of the obtained regioisomers were determined utilizing 2D HMBC NMR techniques as a valuable tool.

**Keywords**

microwave irradiation; phenothiazine; pyrazole; hydrazonyl halides; HMBC; regioselectivity

---


\* Corresponding author. Fax: +966 26400376; Tel: +966 554433416; E-mail: chem\_org@hotmail.com

## 1. Introduction

The phenothiazine structure occurs in various neuroleptic drugs, e.g. chlorpromazine,<sup>1</sup> and antihistaminic drugs, e.g. promethazine.<sup>2</sup> The term "phenothiazines" describes the largest of the five main classes of neuroleptic antipsychotic drugs. These drugs have antipsychotic, and often antiemetic properties, although they may also cause severe side effects such as extrapyramidal symptoms (including akathisia and tardive dyskinesia), hyperprolactinaemia, and the rare but potentially fatal neuroleptic malignant syndrome, as well as substantial weight gain.<sup>3</sup> These side effects associated with phenothiazine drugs have raised a cautionary flag on these drugs.

Phenothiazine antipsychotics are classified into three groups that differ with respect to the substituent on the ring. Hence, there remains a demand for more efficacious and safer phenothiazine derivatives; this can be attained by the synthesis of a large number of novel phenothiazine derivatives for biological screening programmes.

On the other hand, enaminones have proven to be valuable synthons for a wide variety of biologically active heterocyclic ring systems.<sup>4-8</sup> One of these important classes is the pyrazole system.<sup>9-12</sup> Literature reports reveal many synthetic approaches used for the synthesis of pyrazole derivatives, one of the most important approach being the 1,3-dipolar cycloaddition utilizing nitrilimines (generated *insitu* by the action of base on the hydrazonoyl halide) and  $\alpha,\beta$ -unsaturated carbonyl compounds (Scheme 1).<sup>13-15</sup>




### Scheme 1: 1,3-Dipolar cycloaddition reaction

The above reaction proceeds regioselectively to give only one product **A** or **B**. However, to the best of our knowledge, it is frequently difficult to present unequivocal proof of the reaction product structures for this 1,3-dipolar cycloaddition reaction. Therefore, it is crucial to rationalize the observed regioselectivity. Single crystal X-ray is a useful tool for the unambiguous structure determination of the obtained products, but it is sometimes difficult to access a single crystal of the formed product.

Motivated by the aforementioned findings, and in a continuation of our interest in the synthesis of a wide range of heterocyclic systems for biological screening in our laboratory,<sup>16-31</sup> we report herein on the 1,3-dipolar cycloaddition of some nitrilimines to the versatile, *hitherto* unreported *E*-3-(dimethylamino)-1-(10*H*-phenothiazin-2-yl) prop-2-en-1-one (**2**) under both microwave irradiation and conventional methods. This provides a convenient route for obtaining the novel phenothiazine derivatives bearing a pyrazole moiety. Unambiguous structure determination of the obtained regioisomers utilizing 2D NMR techniques as a valuable tool for the identification and characterization of pyrazoles was employed which could facilitate the work of the pharmacologist in the study of the structure activity relationship of bioactive molecules.


## 2. Results and discussion

The reaction of equimolar quantities of 1-(10*H*-phenothiazin-2-yl)ethanone (**1**) and dimethylformamide-dimethylacetal (*DMF-DMA*) was carried out in toluene under microwave irradiation. The key intermediate *E*-3-(dimethylamino)-1-(10*H*-phenothiazin-2-yl)prop-2-en-1-one (**2**) was obtained within 45 min. as evidenced by TLC (Scheme 2), while the same reaction carried out *via* reflux in toluene required 18 h.




**Scheme 2: Synthesis of enaminone 2**

The structure of the enaminone **2** was confirmed by its elemental analysis and spectroscopic data. Its <sup>1</sup>H NMR spectrum displayed two singlet signals at δ 2.88 and 3.13, due to the *N,N*-dimethyl protons, two doublets at δ 5.69 and 7.70 (*J* = 12.4 Hz), due to the olefinic protons, in addition to aromatic proton signals in the region δ 6.66-7.30 and D<sub>2</sub>O exchangeable singlet signal, due to the NH proton at δ 8.68. The value of the coupling constant (*J* = 12.4 Hz) for the ethylenic protons indicates that the enaminone **2** exists exclusively in the *E*-configuration. The reactivity of enaminones, in general, can be attributed to the fact that they have two electron poor centers at C-1 and C-3 in addition to one electron-rich center at C-2, attributed by the delocalization of the lone pair of electrons on the nitrogen atom (Figure 1).




**Figure 1: Structure of Enaminone 2**

The double bond in compound **2** can be looked on as an electron-rich one that may enter into 1,3-dipolar cycloaddition reactions with hydrazonyl halides. On the other hand, there are many types of hydrazonyl halides as represented in Figure 2. Type I are  $\alpha$ -keto hydrazonyl halides, type II are *N*-arylbenzenecarbohydrazonyl halide, type III are oxalodihydrazonyl dihalides and type IV are *N*-aryltrifluoromethylcarbohydrazonyl halides



**Figure 2: Some types of hydrazonyl halides**

These hydrazonyl halides in presence of a base liberate *in situ*, intermediates known as nitrilimines. These can react easily with  $\alpha,\beta$ -unsaturated ketones such as enaminones to afford a pyrazole *via* a 1,3-dipolar cycloaddition reaction. Therefore, our current research is directed to the study of the regioselectivity in the 1,3-dipolar cycloaddition of some nitrilimines (liberated *in situ* for hydrazonyl halides types I and III) with enaminone **2**. Thus, when compound **2** was allowed to react with the nitrilimine **4** (liberated, *in situ*, from the corresponding hydrazonyl halides (Type I) **3** by the action of triethylamine in dioxane under microwave irradiation), it afforded in each case, only one isolable product as shown by TLC analysis (Scheme 3). The times of reactions and yields are shown in Table 1.



### Scheme 3: Reaction of hydrazonyl halides (type I) with enaminone 2

We have three possible products **5**, **7** or **9**. Amidrazone structure **5** was easily ruled out on the basis of the  $^1\text{H}$  NMR spectra of the reaction products. In principle, two isomeric structures, **7a-h** or **9a-h** are possible for the product on the basis of elemental analysis and spectroscopic data of the isolated products. For example, the  $^1\text{H}$  NMR spectra of the isolated products show, in each case, disappearance of  $\text{NMe}_2$  signals, and the two doublets of the olefinic protons, and appearance of a singlet signal corresponding to pyrazole proton in the region  $\delta$  8.96-9.23. The IR spectra of the isolated products, in each case, showed the presence of two carbonyl absorption bands, and the presence of a band due to a NH group (Scheme 3).


To our knowledge, the previously reported results<sup>32-34</sup> for similar reactions based on one dimension  $^1\text{H}$  NMR spectroscopy assume that in the pyrazole ring system, C-4 is more electron-rich carbon than C-5; thus, H-4 is expected to appear at a higher field, typically at a lower chemical shift than H-5, which is

linked to a carbon attached to a nitrogen atom, and therefore is deshielded and typically appeared at a higher chemical shift.


We agree with this assumption to some extent, if we can compare the spectra of two regioisomers. In the present case, we have only one  $^1\text{H}$  NMR spectrum in view of the fact that the reaction proceeded in a regioselective manner. The chemical shift in NMR spectroscopy is considered a tensor not a scalar, so we can not decide if the obtained chemical shift of the pyrazole proton is a lower or higher value.

Therefore, distinction between the two possible regioisomers is very important, so we introduce here, a simple 2D-NMR experiment to unambiguously elucidate the structure of the obtained regioisomer.


Structure elucidation was conveniently achieved on the basis of the long-range C–H connectivities *via*  $^1\text{H}$ - $^{13}\text{C}$  HMBC, (Figure 3a) depending on the correlation between the pyrazole proton with the carbons of the two carbonyl groups. For example, the  $^1\text{H}$ - $^{13}\text{C}$  HMBC spectrum of the isolated product **7a** or **9a**, shows a signal at  $\delta$  193.14 ppm corresponding to the carbonyl carbon due to its correlation peak with the signal at  $\delta$  2.59 ppm assigned to the methyl protons of the acetyl group (Figure 3b).





**a**



b



c




d

**Figure 3:** (a) the  $^1\text{H}$ - $^{13}\text{C}$  HMBC spectrum of the isolated regioisomer **7a** or **9a** (b) correlation between methyl protons and carbonyl group (c) correlation between pyrazole proton and carbonyl group (d) diagnostic correlations in the  $^1\text{H}$ - $^{13}\text{C}$  HMBC (red arrows) for two regioisomer **7a** and **9a**

On the other hand, the signal at  $\delta$  188.96 ppm is attributed to the other carbonyl group, owing to its correlation peak with the signal at  $\delta$  9.02 ppm, easily assigned to the pyrazole proton (Figure 3C). These observations indicate that only one carbonyl functional group correlates to the pyrazole proton ( $^3J_{\text{H-C}}$ ), in accordance with the structure **7a**, in addition to the other observed correlations of the pyrazole protons with C-4 pyrazole ( $^2J_{\text{H-C}}$ ), C-3 pyrazole ( $^3J_{\text{H-C}}$ ) and the deshielded quaternary carbon of the phenyl group ( $^3J_{\text{H-C}}$ ) (Figure 3c and Figure 3d). Therefore, these results confirm the existence of regioisomer **7a** and rule out the alternative structure **9a**.

The formation of novel pyrazole derivatives **7a-h** were assumed to be formed *via* initial 1,3-dipolar cycloaddition of the nitrilimines **4a-h** to the activated double bond in the enaminone **2** to afford the non-isolable dihydropyrazole intermediates **8**, followed by elimination of dimethylamine, yielding the pyrazole derivative **7a-h**.

It is noteworthy that the structure of pyrazole derivatives **7a-h** resulting from type I hydrazonyl halides can be confirmed chemically *via* the reaction of compounds **7a-h** with hydrazine to afford the pyrazolo[3,4-*d*] pyridazine derivatives **10a-h** in almost quantitative yields (Scheme 4). The time of reactions and yields are shown in Table 1.





#### Scheme 4: Synthesis of pyrazolo[3,4-*d*] pyridazine derivatives **10a-h**







The structures of the products **10a-h** were confirmed based on their elemental analysis and spectroscopic data. The IR spectra of compounds **10a-d** showed disappearance of the two carbonyl absorption bands. Also, the IR spectra of


compounds **10e-h** showed appearance of two bands due to the two NH groups. The mass spectra of **10a** showed a peak corresponding to the molecular ion at 407 and its  $^1\text{H}$  NMR spectrum revealed a singlet at  $\delta$  2.49 due to the methyl protons, a  $\text{D}_2\text{O}$  exchangeable singlet signal at  $\delta$  8.79 and a singlet signal at  $\delta$  9.56 due to the pyrazole H-5 proton in addition to aromatic multiplets.





In order to address the advantage of microwave irradiation on the above mentioned reactions, all the previously mentioned reaction were carried out using conventional method *via* reflux in dioxane and/or ethanol (Table 1). The obtained results revealed that the reactions are took a longer time to attain a much lower yield than that obtained using the microwave protocol.

**Table 1: Synthesis of pyrazole 7a-h pyrazolo[3,4-*d*]pyridazine derivatives 10a-h under both Microwave irradiation and conventional method**

Entry	Product	Microwave Irradiation		Conventional Condition	
		Time (min.)	Yield %	Time (h)	Yield %
1	 <p style="text-align: center;"><b>7a</b></p>	120	91	48	69
2	 <p style="text-align: center;"><b>7b</b></p>	120	93	48	70

3		120	93	48	65
	<b>7c</b>				
4		90	89	48	62
	<b>7d</b>				
5		120	90	48	65
	<b>7e</b>				
6		100	91	48	62
	<b>7f</b>				
7		120	90	48	62
	<b>7g</b>				
8		120	88	48	58



13	 <b>10e</b>	30	88	3	80
14	 <b>10f</b>	30	87	3	79
15	 <b>10g</b>	30	90	3	77
16	 <b>10h</b>	30	93	3	83

Thus, microwave irradiation was found to have a beneficial effect on the synthesis of pyrazole derivatives **7a-h** and pyrazolo[3,4-*d*]pyridazine derivatives **10a-h**, in which there was a substantial decrease in the time of above reactions


from 3-48 h under conventional heating to 30min.-2 h. In addition there was a noticeable improvement in the yields of the reactions under microwave irradiations.

Encouraged by the successful characterization of pyrazole derivatives **7a-h**, the reaction protocol was further extended to the reaction of other hydrazonyl halides of type III with enaminone **2**, in order to provide unambiguous structure determination of the obtained regioisomers. It is worth mentioning that the regioisomeric products in this case can not be proved chemically like the regioisomeric product of type I hydrazonyl halides with enaminone **2**.

It is important to mention here, that the reaction of oxalodihydrazonyl dichlorides (**11**) (Type III) with enaminone **2** afforded the regioselective bis pyrazole product **13** or **14**; however, oxalodihydrazonyl dichlorides (**11**) (Type III) were relatively more reactive and sensitive to heat than type I; it required less exposure time to MW irradiation at lower power for completion of the reaction.

The reaction was also performed under conventional conditions, by stirring the reactant at room temperature (Scheme 5).


Reaction of oxalodihydrazonyl dichlorides (**11**) (Type III) with enaminone **2** under microwave irradiation also resulted in exclusive formation of a single regioisomer that may have structure **13** or **14** (Scheme 5). The challenge was to differentiate and determine its structure by NMR spectroscopy.




### Scheme 5: Regioselective synthesis of bis-Pyrazole derivative **13**

We found that  $^1\text{H}$ - $^{13}\text{C}$  HMBC is also a useful tool to unambiguously assign the structure of isolated regioisomers unambiguously.

Structure elucidation of the isolated product **13** or **14** was achieved on the basis of the long-range C–H connectivities *via*  $^1\text{H}$ - $^{13}\text{C}$  HMBC, based on the number of correlations between the pyrazole proton towards carbons that are two and three bonds away (Figure 4a). The presence of four correlations in  $^1\text{H}$ - $^{13}\text{C}$  HMBC spectrum of the isolated product is conclusive evidence for the proposed structure **13** (Figure 4b).





**Figure 4:** (a) number of correlations between pyrazole proton towards carbons in the possible regioselective products **13** and **14**  
 (b)  $^1\text{H}$ - $^{13}\text{C}$  HMBC spectrum of the isolated product

Finally, our efforts will be extended to encompass unambiguous structural characterization of the regioselectivity in 1,3-dipolar cycloaddition reactions with other types of hydrazonyl halides.

### 3. Conclusion

An efficient microwave-assisted protocol for the regioselective synthesis of a series of novel pyrazoles incorporating a phenothiazine moiety is reported. Microwave irradiation offered high yields of pyrazoles in a short reaction time, compared with classical heating. 2D ( $^1\text{H}$ - $^{13}\text{C}$ ) HMBC measurements can be readily utilized for the unambiguous structural characterization of the regioselectivity in the 1,3-dipolar cycloaddition reaction of hydrazonyl halides, type I and type III with enaminones.

## 4. Experimental section

### 4.1. General

All organic solvents were purchased from commercial sources and used as received unless otherwise stated. All other chemicals were purchased from Merck, Aldrich or Acros and used without further purification. Thin-layer chromatography (TLC) was performed on precoated Merck 60 GF254 silica gel plates with a fluorescent indicator, and detection by means of UV light at 254 and 360 nm. The melting points were measured on a Stuart melting point apparatus and are uncorrected. IR spectra were recorded on a Smart iTR which is an ultra-high-performance, versatile Attenuated Total Reflectance (ATR) sampling accessory on the Nicolet iS10 FT-IR spectrometer. The NMR spectra were recorded on a Bruker Avance III 400 (9.4 Tesla, 400.13 MHz for  $^1\text{H}$  and 100.62 MHz for  $^{13}\text{C}$ ) spectrometer with a 5-mm BBFO probe, at 298 K. Chemical shifts ( $\delta$  in ppm) are given relative to internal solvent,  $\text{CDCl}_3$  7.26 for  $^1\text{H}$  and 77.0 for  $^{13}\text{C}$ . ( $^1\text{H}$ - $^{13}\text{C}$ ) gs-HMBC was acquired and processed using standard Bruker NMR software (Topspin 3.2). Mass spectra were recorded on a Thermo ISQ Single Quadrupole GC-MS. Elemental analyses were carried out on a EuroVector instrument C, H, N, S analyzer EA3000 Series.

Microwave experiments were performed using CEM Discover & Explorer SP microwave apparatus (300 W), utilizing 35 ml capped glass reaction vessels Automated power control based on temperature feedback.

$\alpha$ -Ketohydrazoneyl halides **3a-h**<sup>35</sup> and N,N-diphenyloxalodi-hydrazoneyl dichloride (**11**)<sup>36</sup> were prepared according to the reported literature.

## **4.2. General procedure and characterization data**

### **4.2.1. Synthesis of *E*-3-(dimethylamino)-1-(10*H*-phenothiazin-2-yl)prop-2-en-1-one (2):**

**Method A:** To a solution of 1-(10*H*-phenothiazin-2-yl)ethanone (**1**) (2.41g, 10 mmol) in toluene (30 mL), dimethylformamide-dimethylacetal (*DMF-DMA*)

(2.62 mL, 20 mmol) was added and refluxed for 18 h (until no starting materials showed by in TLC). The excess toluene and *DMF-DMA* was distilled off under reduced pressure. The residual solid was taken up in ether (20 mL) and the resulting crystals were collected by filtration, washed thoroughly with ether, dried and finally recrystallized from dry benzene to afford the enaminone **3** in (2.58g, 87 % yield).

**Method B:** This process was performed using microwave irradiation (300 Watt, 100 °C) on the same scale described above. Here the reactants were dissolved in toluene and subjected to microwave irradiation for 45 min. until the starting materials were no longer detectable by TLC. The product was obtained and purified (2.75 g, 93% yield) as described above in conventional reaction .

Orange solid, mp 249-251 °C; IR (KBr)  $\nu/\text{cm}^{-1}$ : 3256 (NH), 1636 (CO);  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  2.88 (s, 3H, CH<sub>3</sub>), 3.13 (s, 3H, CH<sub>3</sub>), 5.69 (d, 1H, =CH-CO,  $J = 12.4$  Hz), 6.66 (d, 1H, ArH,  $J = 8$  Hz), 6.75 (t, 1H, ArH,  $J = 8$  Hz), 6.91 (d, 1H, ArH,  $J = 8$  Hz), 6.94 (d, 1H, ArH,  $J = 8$  Hz), 6.99 (t, 1H, ArH,  $J = 8$  Hz), 7.22 (s, 1H, ArH), 7.30 (d, 1H, ArH,  $J = 8$  Hz), 7.70 (d, 1H, =CH-N,  $J = 12.4$  Hz), 8.68 (s, 1H, NH, D<sub>2</sub>O-exchangeable);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ):  $\delta$  14.16, 39.35, 62.14, 64.86, 116.03, 122.73, 124.31, 131.34, 132.36, 134.11, 137.80, 145.80, 146.31, 156.68, 161.47, 166.13; MS:  $\text{M}^+$  (296); C<sub>17</sub>H<sub>16</sub>N<sub>2</sub>OS (296.39): Anal. Calcd: C, 68.89; H, 5.44; N, 9.45; S, 10.82. Found C, 68.83; H, 5.38; N, 9.40; S, 10.78%.

#### 4.2.2. Typical procedure for the synthesis of pyrazole derivatives 7a-h

**Method A:** To a mixture of enaminone **2** (2.96g, 10 mmol) and the appropriate hydrazone chloride **3a-h** (10 mmol) in dioxane (15 mL), an equivalent amount of triethylamine (10 mmol) was added. The total mixture was placed in a process vial in the microwave, and was irradiated with a power of 300 W to reach a reaction temperature of 140 °C under auto generated pressure. The vial was exposed to microwaves for the required time to complete the reaction. The progress of the reaction was monitored by TLC (eluent; ethylacetate: chloroform). Upon completion of the reaction, the solvent was evaporated under

reduced pressure. The obtained solid product was crystallized using ethanol to afford the corresponding pyrazole derivatives **7a–h**.

**Method B:** To a hot solution of enaminone **2** (10 mmol) and the appropriate hydrazonyl halides **3a–h** (1.39 mL, 10 mmol) in dioxane (25 mL), triethylamine (10 mmol) was added. The reaction mixture was refluxed for 48 h. The solvent was evaporated under reduced pressure. The solid product was crystallized from ethanol to afford the corresponding pyrazole derivatives **7a–h**.

#### 4.2.2.1. *1-(4-(10H-phenothiazine-2-carbonyl)-1-phenyl-1H-pyrazol-3-yl)ethanone (7a)*

Orange solid, mp 258-260 °C; IR (KBr)  $\nu/\text{cm}^{-1}$ : 3406 (NH), 1682, 1645 (CO), 1593 (C=N);  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  2.59 (s, 3H, CH<sub>3</sub>CO), 6.61 (d, 1H, ArH,  $J = 8$  Hz), 6.76 (t, 1H, ArH,  $J = 8$  Hz), 6.92 (d, 1H, ArH,  $J = 8$  Hz), 6.97-7.02 (m, 2H, ArH), 7.07 (s, 1H, ArH), 7.17 (d, 1H, ArH,  $J = 8$  Hz), 7.47 (t, 1H, ArH,  $J = 7.6$  Hz), 7.60 (t, 2H, ArH,  $J = 7.6$  Hz), 7.99 (d, 2H, ArH,  $J = 8$  Hz), 8.73 (s, 1H, NH, D<sub>2</sub>O-exchangeable), 9.02 (s, 1H, pyrazole-5-CH);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ):  $\delta$  27.50, 114.59, 114.98, 115.55, 119.85, 122.63, 123.11, 123.19, 124.09, 126.60, 126.75, 128.49, 130.28, 131.56, 136.91, 137.06, 139.02, 141.59, 142.40, 150.30, 188.96, 193.14; MS:  $\text{M}^+$  (411); C<sub>24</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>S (411.48): Anal. Calcd: C, 70.05; H, 4.16; N, 10.21; S, 7.79. Found C, 69.98; H, 4.12; N, 10.11; S, 7.71%.

#### 4.2.2.2. *1-(1-(4-methylphenyl)-4-(10H-phenothiazine-2-carbonyl)-1H-pyrazol-3-yl)ethanone (7b)*

Orange solid, mp 218-220 °C; IR (KBr)  $\nu/\text{cm}^{-1}$ : 3402 (NH), 1682, 1647 (CO), 1585 (C=N);  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  2.38 (s, 3H, CH<sub>3</sub>), 2.58 (s, 3H, CH<sub>3</sub>CO), 6.60 (d, 1H, ArH,  $J = 8$  Hz), 6.76 (t, 1H, ArH,  $J = 8$  Hz), 6.91 (d, 1H, ArH,  $J = 8$  Hz), 6.97-7.02 (m, 2H, ArH), 7.06 (s, 1H, ArH), 7.17 (d, 1H, ArH,  $J = 8$  Hz), 7.40 (d, 2H, ArH,  $J = 8.4$  Hz), 7.87 (d, 2H, ArH,  $J = 8.4$  Hz), 8.74 (s, 1H, NH, D<sub>2</sub>O-exchangeable), 8.96 (s, 1H, pyrazole-5-CH);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ):  $\delta$

20.99, 27.49, 114.60, 114.98, 115.55, 119.71, 122.62, 123.01, 123.16, 124.03, 126.60, 126.75, 128.48, 130.62, 131.36, 136.81, 137.09, 138.06, 141.59, 142.38, 150.08, 189.01, 193.12; MS:  $m/z$  425 ( $M^+$ );  $C_{25}H_{19}N_3O_2S$  (425.50): Anal. Calcd: C, 70.57; H, 4.50; N, 9.88; S, 7.54. Found C, 70.50; H, 4.46; N, 9.83; S, 7.48%.

**4.2.2.3. 1-(1-(4-fluorophenyl)-4-(10H-phenothiazine-2-carbonyl)-1H-pyrazol-3-yl)ethanone (7c)**

Red solid, mp 253-255 °C; IR (KBr)  $v/cm^{-1}$ : 3345 (NH), 1690, 1636 (CO), 1594 (C=N);  $^1H$  NMR (DMSO- $d_6$ ):  $\delta$  2.60 (s, 3H,  $CH_3CO$ ), 6.59 (d, 1H, ArH,  $J = 8$  Hz), 6.75 (t, 1H, ArH,  $J = 8$  Hz), 6.91 (d, 1H, ArH,  $J = 8$  Hz), 6.98-7.03 (m, 2H, ArH), 7.10 (s, 1H, ArH), 7.19 (d, 1H, ArH,  $J = 8$  Hz), 7.45 (d, 2H, ArH,  $J = 8$  Hz), 7.83 (d, 2H, ArH,  $J = 8$  Hz), 8.75 (s, 1H, NH,  $D_2O$ -exchangeable), 9.02 (s, 1H, pyrazole-5-CH);  $^{13}C$  NMR (DMSO- $d_6$ ):  $\delta$  27.45, 114.63, 115.09, 115.65, 119.82, 122.60, 122.89, 123.19, 124.16, 126.66, 127.31, 128.51, 131.01, 131.43, 137.18, 141.05, 141.50, 142.41, 150.16, 160.97, 188.91, 193.14; MS:  $m/z$  429 ( $M^+$ );  $C_{24}H_{16}FN_3O_2S$  (429.47): Anal. Calcd: C, 67.12; H, 3.76; N, 9.78; S, 7.47. Found C, 67.06; H, 3.70; N, 9.75; S, 7.42%.

**4.2.2.4. 1-(4-(10H-phenothiazine-2-carbonyl)-1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)ethanone (7d)**

Red solid, mp 270-272 °C; IR (KBr)  $v/cm^{-1}$ : 3413 (NH), 1983, 1640 (CO), 1606 (C=N);  $^1H$  NMR (DMSO- $d_6$ ):  $\delta$  2.61 (s, 3H,  $CH_3CO$ ), 6.61 (d, 1H, ArH,  $J = 8$  Hz), 6.76 (t, 1H, ArH,  $J = 8$  Hz), 6.91 (d, 1H, ArH,  $J = 8$  Hz), 6.98-7.03 (m, 2H, ArH), 7.08 (s, 1H, ArH), 7.18 (d, 1H, ArH,  $J = 8$  Hz), 7.99 (d, 2H, ArH,  $J = 8.4$  Hz), 8.24 (d, 2H, ArH,  $J = 8.4$  Hz), 8.74 (s, 1H, NH,  $D_2O$ -exchangeable), 9.16 (s, 1H, pyrazole-5-CH);  $^{13}C$  NMR (DMSO- $d_6$ ):  $\delta$  27.54, 114.46, 115.00, 115.53, 120.30, 122.65, 123.31, 123.49, 124.29, 126.62, 126.75, 127.58, 127.61, 128.50, 132.11, 136.91, 137.06, 141.54, 141.83, 142.42, 150.85, 188.72, 193.12; MS:

$m/z$  479 ( $M^+$ );  $C_{25}H_{16}F_3N_3O_2S$  (479.47): Anal. Calcd: C, 62.62; H, 3.36; N, 8.76; S, 6.69. Found C, 62.57; H, 3.30; N, 8.73; S, 6.64%.

**4.2.2.5. Ethyl 4-(10H-phenothiazine-2-carbonyl)-1-phenyl-1H-pyrazole-3-carboxylate (7e)**

Yellow solid, mp 185-187 °C; IR (KBr)  $v/cm^{-1}$ : 3302 (NH), 1717, 1671 (CO), 1599 (C=N);  $^1H$  NMR (DMSO- $d_6$ ):  $\delta$  1.14 (t, 3H,  $CH_3$ ,  $J = 7.2$  Hz), 4.21 (q, 2H,  $CH_2$ ,  $J = 7.2$  Hz), 6.51 (d, 1H, ArH,  $J = 8$  Hz), 6.78 (t, 1H, ArH,  $J = 8$  Hz), 6.90 (d, 1H, ArH,  $J = 8$  Hz), 6.92-6.96 (m, 2H, ArH), 7.11 (s, 1H, ArH), 7.21 (d, 1H, ArH,  $J = 8$  Hz), 7.37 (t, 1H, ArH,  $J = 8$  Hz), 7.46 (t, 2H, ArH,  $J = 8$  Hz), 7.72 (d, 2H, ArH,  $J = 8$  Hz), 8.76 (s, 1H, NH,  $D_2O$ -exchangeable), 9.19 (s, 1H, pyrazole-5-CH);  $^{13}C$  NMR (DMSO- $d_6$ ):  $\delta$  13.82, 61.75, 114.13, 114.64, 116.65, 120.06, 122.40, 122.72, 123.80, 124.39, 125.92, 126.55, 127.78, 128.29, 129.64, 129.95, 137.19, 139.57, 141.41, 141.68, 143.83, 161.53, 188.43; MS:  $m/z$  441 ( $M^+$ );  $C_{25}H_{19}N_3O_3S$  (441.50): Anal. Calcd: C, 68.01; H, 4.34; N, 9.52; S, 7.26. Found C, 67.94; H, 4.29; N, 9.47; S, 7.22%.

**4.2.2.6. Ethyl 1-(4-methylphenyl)-4-(10H-phenothiazine-2-carbonyl)-1H-pyrazole-3-carboxylate (7f)**

Orange solid, mp 210-212 °C; IR (KBr)  $v/cm^{-1}$ : 3290 (NH), 1717, 1669 (CO), 1603 (C=N);  $^1H$  NMR (DMSO- $d_6$ ):  $\delta$  1.13 (t, 3H,  $CH_3$ ,  $J = 7.2$  Hz), 2.39 (s, 3H,  $CH_3$ ), 4.24 (q, 2H,  $CH_2$ ,  $J = 7.2$  Hz), 6.52 (d, 1H, ArH,  $J = 8$  Hz), 6.76 (t, 1H, ArH,  $J = 8$  Hz), 6.88 (d, 1H, ArH,  $J = 8$  Hz), 6.90-6.99 (m, 2H, ArH), 7.09 (s, 1H, ArH), 7.19 (d, 1H, ArH,  $J = 8$  Hz), 7.40 (d, 2H, ArH,  $J = 8.4$  Hz), 7.79 (d, 2H, ArH,  $J = 8.4$  Hz), 8.71 (s, 1H, NH,  $D_2O$ -exchangeable), 9.16 (s, 1H, pyrazole-5-CH);  $^{13}C$  NMR (DMSO- $d_6$ ):  $\delta$  13.79, 20.89, 61.70, 114.09, 114.60, 116.39, 119.88, 122.34, 122.67, 124.02, 124.41, 125.90, 126.48, 127.79, 128.11, 129.24, 130.10, 137.07, 139.23, 141.50, 141.80, 143.91, 161.37, 188.22; MS:

$m/z$  455 ( $M^+$ );  $C_{26}H_{21}N_3O_3S$  (455.53): Anal. Calcd: C, 68.55; H, 4.65; N, 9.22; S, 7.04. Found C, 68.49; H, 4.58; N, 9.17; S, 7.00%.

**4.2.2.7. Ethyl 1-(4-fluorophenyl)-4-(10H-phenothiazine-2-carbonyl)-1H-pyrazole-3-carboxylate (7g)**

Red solid, mp 196-198 °C; IR (KBr)  $v/cm^{-1}$ : 3289 (NH), 1721, 1663 (CO), 1601 (C=N);  $^1H$  NMR (DMSO- $d_6$ ):  $\delta$  1.17 (t, 3H,  $CH_3$ ,  $J = 7.2$  Hz), 4.24 (q, 2H,  $CH_2$ ,  $J = 7.2$  Hz), 6.58 (d, 1H, ArH,  $J = 8$  Hz), 6.82 (t, 1H, ArH,  $J = 8$  Hz), 6.92-7.00 (m, 3H, ArH), 7.11 (s, 1H, ArH), 7.18 (d, 1H, ArH,  $J = 8$  Hz), 7.61 (d, 2H, ArH,  $J = 8.4$  Hz), 8.98 (d, 2H, ArH,  $J = 8.4$  Hz), 8.75 (s, 1H, NH,  $D_2O$ -exchangeable), 9.23 (s, 1H, pyrazole-5-CH);  $^{13}C$  NMR (DMSO- $d_6$ ):  $\delta$  13.83, 61.80, 113.98, 114.62, 116.47, 121.61, 122.05, 122.80, 123.86, 124.49, 125.82, 126.61, 127.53, 127.81, 130.07, 137.17, 139.60, 141.39, 141.82, 143.92, 160.90, 161.42, 188.29; MS:  $m/z$  459 ( $M^+$ );  $C_{25}H_{18}FN_3O_3S$  (459.49): Anal. Calcd: C, 65.35; H, 3.95; N, 9.14; S, 6.98. Found C, 65.29; H, 3.88; N, 9.09; S, 6.92%.

**4.2.2.8. Ethyl 4-(10H-phenothiazine-2-carbonyl)-1-(4-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxylate (7h)**

Orange solid, mp 202-204 °C; IR (KBr)  $v/cm^{-1}$ : 3311 (NH), 1720, 1673 (CO), 1606 (C=N);  $^1H$  NMR (DMSO- $d_6$ ):  $\delta$  1.13 (t, 3H,  $CH_3$ ,  $J = 7.2$  Hz), 4.19 (q, 2H,  $CH_2$ ,  $J = 7.2$  Hz), 6.66 (d, 1H, ArH,  $J = 8$  Hz), 6.75 (t, 1H, ArH,  $J = 8$  Hz), 6.90 (d, 1H, ArH,  $J = 8$  Hz), 6.97-7.02 (m, 2H, ArH), 7.11 (s, 1H, ArH), 7.29 (d, 1H, ArH,  $J = 8$  Hz), 7.98 (d, 2H, ArH,  $J = 8.4$  Hz), 8.21 (d, 2H, ArH,  $J = 8.4$  Hz), 8.77 (s, 1H, NH,  $D_2O$ -exchangeable), 9.22 (s, 1H, pyrazole-5-CH);  $^{13}C$  NMR (DMSO- $d_6$ ):  $\delta$  14.13, 61.69, 114.46, 115.01, 115.52, 120.36, 121.34, 122.29, 122.67, 123.27, 124.34, 124.45, 126.68, 127.54, 128.20, 128.51, 132.34, 137.08, 140.02, 141.51, 142.13, 144.55, 161.30, 188.85; MS:  $m/z$  509 ( $M^+$ );  $C_{26}H_{18}F_3N_3O_3S$  (509.50): Anal. Calcd: C, 61.29; H, 3.56; N, 8.25; S, 6.29. Found C, 61.22; H, 3.49; N, 8.20; S, 6.23%.

### 4.2.3. Synthesis of pyrazolo[3,4-*d*]pyridazine derivatives 10a-h

**Method A:** To a solution of appropriate pyrazole derivatives **7a-h** (1 mmol) in ethanol (10 mL), hydrazine hydrate (98%) (2mL, 10 mmol) was added. The total mixture was placed in a process vial and was irradiated by microwaves with a power of 300 W to reach a reaction temperature of 140 °C under auto generated pressure for 30 min. The solid was filtered off, washed with ethanol and recrystallized from DMF to afford the corresponding pyrazolo[3,4-*d*]pyridazine derivatives **10a-h**.

**Method B:** A mixture of the appropriate pyrazole derivatives **7a-g** (1 mmol) and hydrazine hydrate (98%), (2mL, 10 mmol) was heated under reflux in ethanol (20 mL) for 3 hour then left to cool to room temperature. The precipitates were collected by filtration, washed with ethanol and dried. Recrystallization from dimethylformamide (DMF) afforded yellow crystals of the corresponding pyrazolo[3,4-*d*]pyridazine derivatives **10a-h**.

#### 4.2.3.1. 2-(7-methyl-2-phenyl-2H-pyrazolo[3,4-*d*]pyridazin-4-yl)-10H-phenothiazine (10a)

Orange solid, mp 284-286 °C; IR (KBr)  $\nu/\text{cm}^{-1}$ : 1590 (C=N);  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  2.87 (s, 3H, CH<sub>3</sub>), 6.71 (d, 1H, ArH,  $J = 8$  Hz), 6.78 (t, 1H, ArH,  $J = 8$  Hz), 6.95 (d, 1H, ArH,  $J = 8$  Hz), 7.02 (t, 1H, ArH,  $J = 8$  Hz), 7.10 (d, 1H, ArH,  $J = 8$  Hz), 7.55-7.58 (m, 2H, ArH), 7.60-7.67 (m, 3H, ArH), 8.20 (d, 2H, ArH,  $J = 8$  Hz), 8.79 (s, 1H, NH, D<sub>2</sub>O-exchangeable), 9.56 (s, 1H, pyrazole-5-CH);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ):  $\delta$  18.48, 113.69, 115.01, 115.29, 116.20, 119.79, 121.85, 122.18, 122.40, 125.08, 126.75, 126.91, 128.24, 129.75, 130.24, 135.94, 139.59, 142.00, 142.78, 144.34, 151.76, 153.07; MS:  $m/z$  407 (M<sup>+</sup>); C<sub>24</sub>H<sub>17</sub>N<sub>5</sub>S (407.49):

Anal. Calcd: C, 70.74; H, 4.21; N, 17.19; S, 7.87. Found C, 70.69; H, 4.14; N, 17.14; S, 7.83%.

**4.2.3.2. 2-(7-methyl-2-(4-methylphenyl)-2H-pyrazolo[3,4-d]pyridazin-4-yl)-10H-phenothiazine (10b)**

Orange solid, mp 256-258 °C; IR (KBr)  $\nu/\text{cm}^{-1}$ : 1587 (C=N);  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  2.40 (s, 3H, CH<sub>3</sub>), 2.88 (s, 3H, CH<sub>3</sub>), 6.70 (d, 1H, ArH,  $J = 8$  Hz), 6.79 (t, 1H, ArH,  $J = 8$  Hz), 6.94 (d, 1H, ArH,  $J = 8$  Hz), 7.01 (t, 1H, ArH,  $J = 8$  Hz), 7.12 (d, 1H, ArH,  $J = 8$  Hz), 7.56-7.59 (m, 2H, ArH), 7.61 (d, 2H, ArH,  $J = 8$  Hz), 8.10 (d, 2H, ArH,  $J = 8$  Hz), 8.79 (s, 1H, NH, D<sub>2</sub>O-exchangeable), 9.56 (s, 1H, pyrazole-5-CH);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ):  $\delta$  18.46, 20.87, 113.65, 115.01, 115.17, 116.18, 119.71, 121.83, 122.11, 122.38, 125.10, 126.76, 126.87, 128.25, 129.80, 130.33, 135.84, 140.06, 142.09, 142.71, 144.39, 151.75, 153.01; MS:  $m/z$  421 ( $\text{M}^+$ ); C<sub>25</sub>H<sub>19</sub>N<sub>5</sub>S (421.52): Anal. Calcd: C, 71.23; H, 4.54; N, 16.61; S, 7.61. Found C, 71.15; H, 4.50; N, 16.56; S, 7.57%.

**4.2.3.3. 2-(2-(4-fluorophenyl)-7-methyl-2H-pyrazolo[3,4-d]pyridazin-4-yl)-10H-phenothiazine (10c)**

Red solid, mp 261-263 °C; IR (KBr)  $\nu/\text{cm}^{-1}$ : 1595 (C=N);  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  2.89 (s, 3H, CH<sub>3</sub>), 6.73 (d, 1H, ArH,  $J = 8$  Hz), 6.79 (t, 1H, ArH,  $J = 8$  Hz), 6.95 (d, 1H, ArH,  $J = 8$  Hz), 7.02 (t, 1H, ArH,  $J = 8$  Hz), 7.13 (d, 1H, ArH,  $J = 8$  Hz), 7.60 (s, 1H, ArH), 7.63 (d, 1H, ArH,  $J = 8$  Hz), 7.78 (d, 2H, ArH,  $J = 8.4$  Hz), 8.04 (d, 2H, ArH,  $J = 8.4$  Hz), 8.78 (s, 1H, NH, D<sub>2</sub>O-exchangeable), 9.61 (s, 1H, pyrazole-5-CH);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ):  $\delta$  18.51, 113.67, 115.01, 115.38, 116.17, 119.90, 122.45, 125.40, 126.10, 126.76, 126.93, 128.26, 129.61, 129.94, 135.77, 139.62, 142.34, 142.75, 144.39, 151.93, 153.31, 160.97; MS:  $m/z$  425 ( $\text{M}^+$ , 22%); C<sub>24</sub>H<sub>16</sub>FN<sub>5</sub>S (425.48): Anal. Calcd: C, 67.75; H, 3.79; N, 16.46; S, 7.54. Found C, 67.70; H, 3.72; N, 16.41; S, 7.49%.

**4.2.3.4. 2-(7-methyl-2-(4-(trifluoromethyl)phenyl)-2H-pyrazolo[3,4-d]pyridazin-4-yl)-10H-phenothiazine (10d)**

Red solid, mp 290-292 °C; IR (KBr)  $\nu/\text{cm}^{-1}$ : 1600 (C=N);  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  2.88 (s, 3H, CH<sub>3</sub>), 6.72 (d, 1H, ArH,  $J = 8$  Hz), 6.79 (t, 1H, ArH,  $J = 8$  Hz), 6.96 (d, 1H, ArH,  $J = 8$  Hz), 7.03 (t, 1H, ArH,  $J = 8$  Hz), 7.12 (d, 1H, ArH,  $J = 8$  Hz), 7.57 (s, 1H, ArH), 7.63 (d, 1H, ArH,  $J = 8$  Hz), 8.06 (d, 2H, ArH,  $J = 8.4$  Hz), 8.49 (d, 2H, ArH,  $J = 8.4$  Hz), 8.81 (s, 1H, NH, D<sub>2</sub>O-exchangeable), 9.75 (s, 1H, pyrazole-5-CH);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ):  $\delta$  18.49, 113.62, 115.03, 115.44, 116.15, 119.99, 122.42, 125.64, 126.00, 126.76, 126.94, 127.54, 127.57, 128.27, 129.50, 129.83, 135.78, 141.96, 142.41, 142.81, 144.58, 151.94, 153.27; MS:  $m/z$  475 (M<sup>+</sup>); C<sub>25</sub>H<sub>16</sub>F<sub>3</sub>N<sub>5</sub>S (475.49): Anal. Calcd: C, 63.15; H, 3.39; N, 14.73; S, 6.74. Found C, 63.09; H, 3.32; N, 14.68; S, 6.70%.

**4.2.3.5. 4-(10H-phenothiazin-2-yl)-2-phenyl-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one (10e)**

Yellow solid, mp 281-283 °C; IR (KBr)  $\nu/\text{cm}^{-1}$ : 3309, 3291 (NH), 1653 (CO), 1601 (C=N);  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  6.70 (d, 1H, ArH,  $J = 8$  Hz), 6.80 (t, 1H, ArH,  $J = 8$  Hz), 6.95 (d, 1H, ArH,  $J = 8$  Hz), 7.02 (t, 1H, ArH,  $J = 8$  Hz), 7.07 (d, 1H, ArH,  $J = 8$  Hz), 7.28 (s, 1H, ArH), 7.39 (d, 1H, ArH,  $J = 8$  Hz), 7.54 (t, 1H, ArH,  $J = 8$  Hz), 7.64 (t, 2H, ArH,  $J = 8$  Hz), 8.13 (d, 2H, ArH,  $J = 8$  Hz), 8.75 (s, 1H, NH, D<sub>2</sub>O-exchangeable), 9.35 (s, 1H, pyrazole-5-CH), 12.65 (s, 1H, NH, D<sub>2</sub>O-exchangeable);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ):  $\delta$  113.02, 115.00, 116.24, 118.57, 118.73, 121.20, 122.32, 126.31, 126.76, 126.90, 128.22, 129.34, 130.25, 134.78, 139.45, 141.21, 141.99, 142.75, 143.24, 144.56, 156.36; MS:  $m/z$  409 (M<sup>+</sup>, 22%); C<sub>23</sub>H<sub>15</sub>N<sub>5</sub>OS (409.46): Anal. Calcd: C, 67.47; H, 3.69; N, 17.10; S, 7.83. Found C, 67.39; H, 3.60; N, 17.06; S, 7.75%.

**4.2.3.6. 2-(4-methylphenyl)-4-(10H-phenothiazin-2-yl)-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one (10f)**

Yellow solid, mp > 300 °C; IR (KBr)  $\nu/\text{cm}^{-1}$ : 3311, 3294 (NH), 1657 (CO), 1603 (C=N);  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  2.40 (s, 3H, CH<sub>3</sub>), 6.68 (d, 1H, ArH,  $J = 8$  Hz), 6.81 (t, 1H, ArH,  $J = 8$  Hz), 6.95 (d, 1H, ArH,  $J = 8$  Hz), 7.01 (t, 1H, ArH,  $J = 8$  Hz), 7.09 (d, 1H, ArH,  $J = 8$  Hz), 7.25 (s, 1H, ArH), 7.37 (d, 1H, ArH,  $J = 8$  Hz), 7.42 (d, 2H, ArH,  $J = 8$  Hz), 7.66 (d, 2H, ArH,  $J = 8$  Hz), 8.72 (s, 1H, NH, D<sub>2</sub>O-exchangeable), 9.32 (s, 1H, pyrazole-5-CH), 12.61 (s, 1H, NH, D<sub>2</sub>O-exchangeable);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ):  $\delta$  18.47, 113.01, 115.05, 116.22, 118.53, 118.70, 121.24, 122.29, 126.27, 126.76, 126.91, 128.24, 129.32, 130.28, 134.75, 139.48, 141.26, 142.10, 142.83, 143.31, 144.55, 155.53; MS:  $m/z$  423.49 (M<sup>+</sup>); C<sub>24</sub>H<sub>17</sub>N<sub>5</sub>OS (423): Anal. Calcd: C, 68.07; H, 4.05; N, 16.54; S, 7.57. Found C, 68.00; H, 4.01; N, 16.45; S, 7.51%.

**4.2.3.7. 2-(4-fluorophenyl)-4-(10H-phenothiazin-2-yl)-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one (10g)**

Orange solid, mp > 300 °C; IR (KBr)  $\nu/\text{cm}^{-1}$ : 3315, 3301 (NH), 1660 (CO), 1595 (C=N);  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  6.73 (d, 1H, ArH,  $J = 8$  Hz), 6.80 (t, 1H, ArH,  $J = 8$  Hz), 6.95 (d, 1H, ArH,  $J = 8$  Hz), 7.03 (t, 1H, ArH,  $J = 8$  Hz), 7.12 (d, 1H, ArH,  $J = 8$  Hz), 7.30 (s, 1H, ArH), 7.41 (d, 1H, ArH,  $J = 8$  Hz), 7.76 (d, 2H, ArH,  $J = 8.4$  Hz), 8.05 (d, 2H, ArH,  $J = 8.4$  Hz), 8.76 (s, 1H, NH, D<sub>2</sub>O-exchangeable), 9.32 (s, 1H, pyrazole-5-CH), 12.68 (s, 1H, NH, D<sub>2</sub>O-exchangeable);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ):  $\delta$  113.11, 115.16, 116.18, 118.46, 119.02, 122.42, 126.11, 126.75, 126.93, 128.27, 129.51, 129.98, 134.86, 139.60, 141.32, 142.05, 142.75, 143.30, 144.50, 155.59, 161.09; MS:  $m/z$  427 (M<sup>+</sup>); C<sub>23</sub>H<sub>14</sub>FN<sub>5</sub>OS (427.45): Anal. Calcd: C, 64.63; H, 3.30; N, 16.38; S, 7.50. Found C, 64.57; H, 3.26; N, 16.36; S, 7.47%.

**4.2.3.8. 4-(10H-phenothiazin-2-yl)-2-(4-(trifluoromethyl)phenyl)-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one (10h)**

Orange solid, mp > 300 °C; IR (KBr)  $\nu/\text{cm}^{-1}$ : 3321, 3314 (NH), 1662 (CO), 1603 (C=N);  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  6.71 (d, 1H, ArH,  $J = 8$  Hz), 6.79 (t, 1H, ArH,  $J = 8$  Hz), 6.96 (d, 1H, ArH,  $J = 8$  Hz), 7.05 (t, 1H, ArH,  $J = 8$  Hz), 7.15 (d, 1H, ArH,  $J = 8$  Hz), 7.33 (s, 1H, ArH), 7.46 (d, 1H, ArH,  $J = 8$  Hz), 8.09 (d, 2H, ArH,  $J = 8.4$  Hz), 8.43 (d, 2H, ArH,  $J = 8.4$  Hz), 8.76 (s, 1H, NH,  $\text{D}_2\text{O}$ -exchangeable), 9.34 (s, 1H, pyrazole-5-CH), 12.64 (s, 1H, NH,  $\text{D}_2\text{O}$ -exchangeable);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ):  $\delta$  113.12, 115.10, 116.17, 118.85, 119.93, 121.20, 122.44, 124.60, 126.31, 126.76, 126.91, 128.23, 129.42, 130.11, 135.06, 139.66, 141.41, 142.09, 142.77, 143.34, 144.56, 155.54; MS:  $m/z$  477 ( $\text{M}^+$ );  $\text{C}_{24}\text{H}_{14}\text{F}_3\text{N}_5\text{OS}$  (477.46): Anal. Calcd: C, 60.37; H, 2.96; N, 14.67; S, 6.72. Found C, 60.31; H, 2.90; N, 14.62; S, 6.68%.

#### 4.2.4. Synthesis of 4,4'-di(10H-phenothiazine-2-carbonyl)-1,1'-diphenyl-1H,1'H-3,3'-bipyrazole (13)

**Method A:** To a mixture of enaminone **2** (2.96 g, 10 mmol) and the appropriate *N,N'*-diphenyloxalodihydrazonoyl dichloride (**11**) (1.54 g, 5 mmole) in dioxane (15 ml), an equivalent amount of triethylamine (10 mmol) was added. The total mixture was placed in a process vial and was irradiated by microwaves with a power of 50 W to reach a reaction temperature of 70 °C under auto generated pressure. The vial was exposed to microwaves for the required time to complete the reaction. The progress of the reaction was monitored by TLC (eluent; ethylacetate: chloroform). Upon completion of the reaction, the solvent was evaporated under reduced pressure to obtain the solid product in (3.28 g, 89% yield). The obtained solid product was crystallized using ethanol to afford the corresponding bipyrazole derivative **13**.

**Method B:** This process was performed with stirring at room temperature on the same scale described above for the microwave reaction. The reactants were stirred in dioxane for 24 h until the starting materials were no longer detectable

by TLC. The product was obtained and purified (2.43 g, 66% yield) as described above in microwave reaction .

Brown solid, mp 152-154 °C; IR (KBr)  $\nu/\text{cm}^{-1}$ : 3394 (NH), 1651 (CO), 1590 (C=N);  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  6.61 (d, 1H, ArH,  $J = 8$  Hz), 6.76 (t, 1H, ArH,  $J = 8$  Hz), 6.91 (d, 1H, ArH,  $J = 8$  Hz), 6.98-7.03 (m, 2H, ArH), 7.08 (s, 1H, ArH), 7.18 (d, 1H, ArH,  $J = 8$  Hz), 7.47 (t, 1H, ArH,  $J = 7.6$  Hz), 7.60 (t, 2H, ArH,  $J = 7.6$  Hz), 8.00 (d, 2H, ArH,  $J = 8$  Hz), 8.74 (s, 1H, NH, D<sub>2</sub>O-exchangeable), 9.03 (s, 1H, pyrazole-5-CH);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ):  $\delta$  114.55, 114.98, 115.56, 119.85, 122.68, 123.19, 123.24, 124.19, 126.65, 126.74, 128.49, 130.34, 131.66, 136.99, 137.08, 139.06, 142.56, 142.63, 143.42, 195.34; MS:  $\text{M}^+$  (736); C<sub>44</sub>H<sub>28</sub>N<sub>6</sub>O<sub>2</sub>S<sub>2</sub> (736.86): Anal. Calcd: C, 71.72; H, 3.83, N, 11.41; S, 8.70. Found C, 71.66; H, 3.78; N, 11.39; S, 8.62%.


#### References

- [1] Liu, X; De Haan, S. *Cochrane Database Syst Rev*, **2009**, 2, CD007778.
- [2] Tarkkila, P; Tôrn, K; Tuominen, M; Lindgren, L. *Acta Anaesthesiol Scand* **1995**, 39, 983–986.
- [3] Dale, M.M.; Rang, H. P. in Rang & Dale's pharmacology, 7<sup>th</sup> edition, Elsevier/Edinburgh : Churchill Livingstone, 2012.
- [4] Stanovnik, B.; Svete, J. *Chem. Rev.* **2004**, 104, 2433-2480.
- [5] Stanovnik, B.; Svete, J. *Synlett* **2000**, 1077-1091.
- [6] Selic, L.; Jaksč, R.; Lampic, K.; Golic, L.; Golic Grdadolnik, S.; Stanovnik, B. *Helv. Chim. Acta* **2000**, 83, 2802-2811
- [7] Selic, L.; Stanovnik, B. *Tetrahedron* **2001**, 57, 3159-3164.
- [8] Selic, L.; Recnik, S.; Stanovnik, B. *Heterocycles*, **2002**, 58, 577-585.


- [9] Kost, A. N. I.; Grandberg, I. *Adv. Heterocycl. Chem.* **1966**, *6*, 347-429.
- [10] Elguero, J.; Goya, P.; Jagerovic, N.; Silva, A. M. S. In *Targets in Heterocyclic Systems*; Attanasi, O. A., Spinelli, D., Eds.; Springer: New York, NY, 2002; Vol. 6, pp 52-98.
- [11] Yet, L. In *Comprehensive Heterocyclic Chemistry III*; Katritzky, A. R., Ramsden, C. A., Scriven, E. F. V., Taylor, R. J. K., Eds.; Elsevier: Oxford, 2008; Vol. 4, pp 1-141.
- [12] Fustero, S.; Sanchez-Rosell, M.; Barrio, P.; Simon-Fuentes, A. *Chem. Rev.* **2011**, *111*, 6984-7034.
- [13] Farag, A. M.; Mayhoub, A. S.; Barakat, S. E.; Bayomi, A. H. *Bio. Org. Med. Chem.*, **2008**, *16*, 881-889.
- [14] Donohue, S. R.; Halldin, C.; Pike, V. W. *Tetrahedron Letts.*, **2008**, *49* , 2789-2791.
- [15] Huisgen, R. *Angew. Chem. Int. Ed.*, 1963, *2*, 565-568.
- [16] Abd El-Rahman, N.M.; Saleh, T.S.; Mady, M.F.; *Ultrason. Sonochem.* **2009**, *16*, 70-74.
- [17] Saleh, T. S.; Abd-El-Rahman, N. M. *Ultrasonics Sonochemistry*, **2009**, *16*, 237-242.
- [18] Saleh, T. S.; Abd El-Rahman, N. M.; Elkateb, A. A.; Shaker, N. O.; Mahmoud, N. A.; Gabal. S. A.; *Ultrasonics Sonochemistry*, **2012**, *19*, 491-497.
- [19] Ahmed, N. S.; Saleh, T. S.; El-Mossalamy, E. H.; *Current organic chemistry*, **2013**, *17*, 194-202.

- [20] Saleh, T.S.; Eldebss, T.M.A.; Albishri, H.M.; *Ultrason. Sonochem.*, **2012**, *19*, 49-55.
- [21] Shaaban, M.R.; Saleh, T.S.; Farag, A.M.; *Heterocycles*, **2009**, *78*, 151-159.
- [22] Shaaban, M.R.; Saleh, T.S.; Farag, A.M.; *Heterocycles* **2009**, *78*, 699-706.
- [23] Abdel-Aziz, H.A.; Saleh, T.S.; El-Zahabi, H.S.A.; *Arch. Pharm.*, **2010**, *343*, 24-30.
- [24] Mokhtar, M.; Saleh, T. S.; Basahel, S. N.; *Journal of Molecular Catalysis A: Chemical*, **2012**, *353–354*, 122-131.
- [25] Albogami, A.S.; *Asian Journal of Chemistry*, **2011**, *23*, 3045-3049.
- [26] Albogami, A.S.; Almajid, A. M.; Al-Saad, M. A.; Mosa, A. M.; Almazroa, S. A.; Alkathlan, H. Z.; *Molecules*, **2009**, *14*, 2147-2159.
- [27] Albogami, A. S.; *Synthetic Communications*, **2011**, *41*, 2952-2958.
- [28] Albogami, A. S.; Karama, U.; Mousa, A. A.; Khan, V.; Al-mazroa, S. A.; Alkathlan H. Z.; *Oriental Journal Of Chemistry*, **2012**, *28*, 619-626.
- [29] Abdelrazek, F. M.; Salaheldin, A. M.; Mekky, A. E. M. *Tetrahedron*, **2001**, *57*, 1813-1817
- [30] Abdelrazek, F. M.; Salaheldin, A. M.; Mekky, A. E. M. *Tetrahedron*, **2001**, *57*, 6787-6791.
- [31] Elneairy, M. A. A.; Mekky, A.E. M.; Ahmed, A. A. M. *Journal of Sulfur Chemistry*, 2012, *33*, 373–383.
- [32] Alzaydi, K. M. *Molecules*, **2003**, *8*, 541-555
- [33] Al-Zaydi K. M., Hafez, E. A. A. *J. Chem. Res.*, **1999**, 360-361.

- [34] Shaaban, M.R.; Saleh, T.S.; Osman, F.H.; Farag, A.M.; *J. Heterocycl. Chem.*, **2007**, *44*, 177-181.
- [35] Farag, A. M.; Algharib, M. S.; *Org. Prep and Proced. Int.*, **1988**, *20*, 521-526.
- [36] Grundmann, W.; Datta, S.K.; Sprecher, R.F. *Annalen der Chemie-justus Liebig*, **1971**, *88*, 744-748.



7a



7a

— 193.1434

— 188.9623

— 150.3034

— 142.4000

— 141.5917

— 139.0299

— 137.0682

— 136.9179

— 131.5645

— 130.2803

— 128.4916

— 126.7566

— 126.6091

— 124.0994

— 123.1917

— 123.1182

— 122.6328


— 119.8536

— 115.5569


— 114.9888

— 114.5984


— 27.5060




7a




7a



7a



7b



7b

— 193.1231

— 189.0139

— 150.0878

— 142.3864

— 141.5987

— 138.0600

— 137.0905

— 136.8123

— 131.3665

— 130.6278

— 128.4865

— 126.7576

— 126.6022

— 124.0399

— 123.1608

— 123.0196

— 122.6296

— 119.7175

— 115.5552

— 114.9855

— 114.6073

40.5658

40.3576

40.1487

39.9400

39.7315

39.5225

39.3140

— 27.4979

— 20.9900


200

150


100

50


[ppm]




7d




7d




7d




7d




7d




7e



7e



7g



7g

188.2967


161.4245  
160.9001

143.9289  
141.8243  
141.3900  
139.6086  
137.1765  
130.0716  
127.8199  
127.5325  
126.6107  
125.8268  
124.4999  
123.8675  
122.8011  
122.0503  
121.6151  
116.4796  
114.6284  
113.9825

61.8037

40.5757  
40.3671  
40.1583  
39.9498  
39.7409  
39.5322  
39.3236

13.8343




150

100

50

[ppm]

7h



7h


— 187.8503

— 161.3010

144.5509  
142.1334  
141.5104  
140.0234  
137.0852  
132.3430  
128.5181  
128.2086  
127.5402  
126.6851  
124.4503  
124.3480  
123.2719  
122.6712  
122.2989  
121.3416  
120.3630  
115.5288  
115.0150  
114.4695

— 61.6981

— 14.1329




150

100

50

[ppm]

10a



10a

153.0764  
151.7691

144.3416  
142.7803  
142.0006  
139.5958


135.9418

130.2484  
129.7531  
128.2480  
126.9159  
126.7527  
125.0830  
122.4047


122.1846  
121.8588  
119.7920  
116.2040  
115.2968  
115.0131  
113.6969

40.1578  
39.9494  
39.7405


18.4860




10d




10d



10e



10e




9.0315  
8.7404  
8.0162  
7.9996  
7.6277  
7.6098  
7.5889  
7.4911  
7.4727  
7.4541  
7.1962  
7.1762  
7.0845  
7.0396  
7.0300  
7.0270  
7.0197  
7.0119  
6.9922  
6.9845  
6.9830  
6.9282  
6.9098  
6.7886  
6.7699  
6.7512  
6.6233  
6.6049

0.9912  
0.9170  
1.9837  
1.9905  
0.9835  
0.9877  
0.9797  
1.9084  
1.1036  
1.0883  
0.9634


3.3615

2.5090



— 195.3400

143.4245  
142.6329  
142.5694  
139.0695  
137.0865  
136.9975  
131.6618  
130.3405  
128.4996  
126.7466  
126.6591  
124.1995  
123.2414  
123.1992  
122.6824  
119.8533  
115.5665  
114.9864  
114.5536





150

100

50


[ppm]






Selected region for  $^1\text{H}$ - $^{13}\text{C}$  HMBC correlations

	$\delta$	assign	HMBC
<b>7a</b>	2.59	CH <sub>3</sub>	193.14 (CO), 150.30 (C-3)
	9.02	H-5	188.96 (CO), 150.30 (C-3), 139.02 (C-i), 123.11(C-4)



Selected region for  $^1\text{H}$ - $^{13}\text{C}$  HMBC correlations

	$\delta$	assign	HMBC
<b>7d</b>	2.61	CH <sub>3</sub>	193.12 (CO), 150.85 (C-3)
	9.16	H-5	188.72 (CO), 150.85 (C-3), 141.54 (C-i), 123.31(C-4)



Selected region for  $^1\text{H}$ - $^{13}\text{C}$  HMBC correlations

	$\delta$	assign	HMBC
<b>13</b>	9.03	H-5	195.34 (CO), 143.42 (C-3), 139.06 (C-i), 123.19(C-4)